THERAPEUTIC AREAS

CHRONIC SINUSITIS


Chronic rhinosinusitis (CRS) impacts approximately 12% of the general population, or around 900 million patients.

0

CHRONIC RHINITIS


Persistent moderate to severe rhinitis impacts approximately 19% of the general population, or around 1.4 billion patients.

0

20%

20% of patients suffering from chronic sinusitis face treatment failure.

25%

25% of patients suffering from Rhinitis face treatment failure.

OUR TECHNOLOGICAL PLATFORM

In chronic sinusitis and rhinitis, 20% to 25% of patients do not respond to drug treatment. There is a need for non surgical minimally invasive therapeutic alternatives. Dianosic develops an Active Resorbable Intranasal Scaffold (ARIS) technological platform with dedicated applications in chronic rhinitis (ARIS-R) and chronic sinusitis (ARIS-S). Those highly versatile, drug-eluting, long-term resorbable polymer solutions will transform the management of those debilitating diseases.

 


Long term resorbable solutions

6 months (ARIS-R)
12 months (ARIS-S)

Minimally invasive & easy to use

No prior surgery required

100% compliance

Implantable “in-office”

Quick return to home

Reduced budget impact (hospitals, insurers)

ARIS-S PROJECT PROGRESS

POC
PROTOTYPING
PRECLINICAL

ARIS-R PROJECT PROGRESS

POC
PROTOTYPING
PRECLINICAL